# Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

> **NCT00504543** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 311 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** AEB071
- **DRUG:** Certican
- **DRUG:** Neoral

## Key facts

- **NCT ID:** NCT00504543
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504543, "Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00504543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*